Oncolytics Biotech Inc (ONC) - Net Assets

Latest as of June 2025: CA$6.09 Million CAD ≈ $4.40 Million USD

Based on the latest financial reports, Oncolytics Biotech Inc (ONC) has net assets worth CA$6.09 Million CAD (≈ $4.40 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$19.97 Million ≈ $14.45 Million USD) and total liabilities (CA$13.88 Million ≈ $10.04 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Oncolytics Biotech Inc (ONC) asset resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets CA$6.09 Million
% of Total Assets 30.48%
Annual Growth Rate -0.58%
5-Year Change -75.83%
10-Year Change -75.75%
Growth Volatility 77.45

Oncolytics Biotech Inc - Net Assets Trend (1999–2024)

This chart illustrates how Oncolytics Biotech Inc's net assets have evolved over time, based on quarterly financial data. Also explore Oncolytics Biotech Inc balance sheet assets for the complete picture of this company's asset base.

Annual Net Assets for Oncolytics Biotech Inc (1999–2024)

The table below shows the annual net assets of Oncolytics Biotech Inc from 1999 to 2024. For live valuation and market cap data, see ONC market cap.

Year Net Assets Change
2024-12-31 CA$5.98 Million
≈ $4.33 Million		 -78.29%
2023-12-31 CA$27.56 Million
≈ $19.94 Million		 +4.00%
2022-12-31 CA$26.50 Million
≈ $19.17 Million		 -26.59%
2021-12-31 CA$36.10 Million
≈ $26.11 Million		 +45.84%
2020-12-31 CA$24.75 Million
≈ $17.91 Million		 +23041.96%
2019-12-31 CA$-107.89K
≈ $-78.05K		 -101.74%
2018-12-31 CA$6.20 Million
≈ $4.48 Million		 -25.21%
2017-12-31 CA$8.28 Million
≈ $5.99 Million		 -22.51%
2016-12-31 CA$10.69 Million
≈ $7.73 Million		 -56.68%
2015-12-31 CA$24.67 Million
≈ $17.85 Million		 +78.55%
2014-12-31 CA$13.82 Million
≈ $10.00 Million		 -37.79%
2013-12-31 CA$22.21 Million
≈ $16.07 Million		 +50.22%
2012-12-31 CA$14.79 Million
≈ $10.70 Million		 -49.91%
2011-12-31 CA$29.52 Million
≈ $21.35 Million		 -29.60%
2010-12-31 CA$41.93 Million
≈ $30.33 Million		 +27.67%
2009-12-31 CA$32.84 Million
≈ $23.76 Million		 +247.44%
2008-12-31 CA$9.45 Million
≈ $6.84 Million		 -66.19%
2007-12-31 CA$27.96 Million
≈ $20.23 Million		 -9.22%
2006-12-31 CA$30.80 Million
≈ $22.28 Million		 -30.71%
2005-12-31 CA$44.45 Million
≈ $32.16 Million		 +15.79%
2004-12-31 CA$38.39 Million
≈ $27.77 Million		 +53.46%
2003-12-31 CA$25.02 Million
≈ $18.10 Million		 +51.08%
2002-12-31 CA$16.56 Million
≈ $11.98 Million		 +3.79%
2001-12-31 CA$15.95 Million
≈ $11.54 Million		 -19.89%
2000-12-31 CA$19.92 Million
≈ $14.41 Million		 +187.47%
1999-12-31 CA$6.93 Million
≈ $5.01 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Oncolytics Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 47713853800.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock CA$438.19 Million 7323.97%
Other Components CA$45.50 Million 760.54%
Total Equity CA$5.98 Million 100.00%

Oncolytics Biotech Inc Competitors by Market Cap

The table below lists competitors of Oncolytics Biotech Inc ranked by their market capitalization.

Company Market Cap
Excelliance MOS
TWO:5299
 $142.53 Million
Bank Dinar Indonesia Tbk PT
JK:DNAR
 $142.54 Million
SKYX Platforms Corp
NASDAQ:SKYX
 $142.61 Million
Cashbil
JSE:CSB
 $142.64 Million
Limes Schlosskliniken AG
XETRA:LIK
 $142.49 Million
Leifheit Aktiengesellschaft
F:LEI
 $142.42 Million
DongKook Pharmaceutical Co. Ltd
KQ:086450
 $142.36 Million
PT Satu Visi Putra Tbk
JK:VISI
 $142.34 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Oncolytics Biotech Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 27,563,000 to 5,983,000, a change of -21,580,000 (-78.3%).
  • Net loss of 31,710,000 reduced equity.
  • Share repurchases of 65,000 reduced equity.
  • New share issuances of 6,919,000 increased equity.
  • Other comprehensive income decreased equity by 544,000.
  • Other factors increased equity by 3,820,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CA$-31.71 Million -530.0%
Share Repurchases CA$65.00K -1.09%
Share Issuances CA$6.92 Million +115.64%
Other Comprehensive Income CA$-544.00K -9.09%
Other Changes CA$3.82 Million +63.85%
Total Change CA$- -78.29%

Book Value vs Market Value Analysis

This analysis compares Oncolytics Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 199.28x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 1.33x to 199.28x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1999-12-31 CA$11.24 CA$14.90 x
2000-12-31 CA$10.89 CA$14.90 x
2001-12-31 CA$8.20 CA$14.90 x
2002-12-31 CA$7.44 CA$14.90 x
2003-12-31 CA$10.19 CA$14.90 x
2004-12-31 CA$12.77 CA$14.90 x
2005-12-31 CA$12.91 CA$14.90 x
2006-12-31 CA$8.06 CA$14.90 x
2007-12-31 CA$6.57 CA$14.90 x
2008-12-31 CA$2.17 CA$14.90 x
2009-12-31 CA$6.34 CA$14.90 x
2010-12-31 CA$6.38 CA$14.90 x
2011-12-31 CA$3.95 CA$14.90 x
2012-12-31 CA$1.85 CA$14.90 x
2013-12-31 CA$2.53 CA$14.90 x
2014-12-31 CA$1.49 CA$14.90 x
2015-12-31 CA$2.08 CA$14.90 x
2016-12-31 CA$0.85 CA$14.90 x
2017-12-31 CA$0.59 CA$14.90 x
2018-12-31 CA$0.39 CA$14.90 x
2019-12-31 CA$0.00 CA$14.90 x
2020-12-31 CA$0.61 CA$14.90 x
2021-12-31 CA$0.67 CA$14.90 x
2022-12-31 CA$0.46 CA$14.90 x
2023-12-31 CA$0.41 CA$14.90 x
2024-12-31 CA$0.07 CA$14.90 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Oncolytics Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -530.00%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 3.37x
  • Recent ROE (-530.00%) is below the historical average (-104.16%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1999 -8.29% -57446200.00% 0.00x 1.03x CA$-1.27 Million
2000 -18.14% -1165.53% 0.01x 1.09x CA$-5.60 Million
2001 -38.68% 0.00% 0.00x 1.20x CA$-7.77 Million
2002 -36.79% -2916.44% 0.01x 1.09x CA$-7.75 Million
2003 -34.15% -2727.07% 0.01x 1.04x CA$-11.05 Million
2004 -33.75% -1851.52% 0.02x 1.03x CA$-16.80 Million
2005 -28.75% -1631.47% 0.02x 1.04x CA$-17.23 Million
2006 -46.42% 0.00% 0.00x 1.09x CA$-17.38 Million
2007 -55.94% 0.00% 0.00x 1.10x CA$-18.44 Million
2008 -185.66% 0.00% 0.00x 1.48x CA$-18.50 Million
2009 -51.75% 0.00% 0.00x 1.13x CA$-20.28 Million
2010 -47.63% 0.00% 0.00x 1.06x CA$-24.17 Million
2011 -98.39% 0.00% 0.00x 1.22x CA$-32.00 Million
2012 -245.99% -749.73% 0.22x 1.49x CA$-37.85 Million
2013 -105.94% 0.00% 0.00x 1.27x CA$-25.75 Million
2014 -134.74% 0.00% 0.00x 1.24x CA$-20.00 Million
2015 -55.62% 0.00% 0.00x 1.11x CA$-16.19 Million
2016 -141.63% 0.00% 0.00x 1.38x CA$-16.21 Million
2017 -188.52% 0.00% 0.00x 2.19x CA$-16.45 Million
2018 -275.00% 0.00% 0.00x 2.40x CA$-17.66 Million
2019 0.00% 0.00% 0.00x 0.00x CA$-45.54 Million
2020 -78.98% 0.00% 0.00x 1.39x CA$-22.03 Million
2021 -72.87% 0.00% 0.00x 1.27x CA$-29.91 Million
2022 -93.71% 0.00% 0.00x 1.41x CA$-27.49 Million
2023 -100.69% 0.00% 0.00x 1.41x CA$-30.51 Million
2024 -530.00% 0.00% 0.00x 3.37x CA$-32.31 Million

Industry Comparison

This section compares Oncolytics Biotech Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $16,982,591
  • Average return on equity (ROE) among peers: -57.58%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Oncolytics Biotech Inc (ONC) CA$6.09 Million -8.29% 2.28x $142.51 Million
Appili Therapeutics Inc (APLI) $-13.40 Million 0.00% 0.00x $1.86 Million
Aptose Biosciences Inc (APS) $93.93 Million -27.98% 0.07x $4.36 Million
Arch Biopartners Inc (ARCH) $-563.41K 0.00% 0.00x $20.88 Million
Biomind Labs Inc (BMND) $-1.30 Million 0.00% 0.00x $6.98 Million
Cybin Inc (CYBN) $76.16 Million -88.81% 0.10x $301.37 Million
Eupraxia Pharmaceuticals Inc (EPRX) $5.11 Million -84.55% 0.14x $393.86 Million
Devonian Health Group Inc (GSD) $7.52 Million -44.48% 0.94x $20.01 Million
Helix BioPharma Corp. (HBP) $6.22 Million -280.21% 0.22x $116.58 Million
Hemostemix Inc (HEM) $-4.05 Million 0.00% 0.00x $8.18 Million
Universal Ibogaine Inc (IBO) $197.12K -49.77% 0.10x $1.13 Million

About Oncolytics Biotech Inc

TO:ONC Canada Biotechnology
Market Cap
$1.08 Billion
CA$1.50 Billion CAD
Market Cap Rank
#17830 Global
#576 in Canada
Share Price
CA$14.90
Change (1 day)
-1.32%
52-Week Range
CA$0.45 - CA$18.60
All Time High
CA$18.60
Categories
Companies in Canada Biotechnology
About

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal aden… Read more